Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 3,874 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Working Memory
Interventions: Transcranial alternating current stimulation (tACS); Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 45 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: SARS-CoV-2 Infection, COVID-19
Interventions: iCura COVID-19 Antigen Rapid Home Test, RT-PCR Test; Device · Diagnostic Test
Lead sponsor: New Day Diagnostics; Network
Eligibility: 2 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Anaheim, California • Knoxville, Tennessee

Conditions: HCV Infection
Interventions: ABT-450, ritonavir; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Waukegan, Illinois

Conditions: Prematurity, Respiratory Disease
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 1 Day to 7 Days
Enrollment: 835 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 13
States / cities: Oakland, California • San Francisco, California • Indianapolis, Indiana + 8 more

Conditions: Diabetic Retinal Disease
Interventions: Visual Acuity, Reading Speed, Visual Field testing, Contrast sensitivity, Electroretinography (ERG) and pupillography in light- and dark-adapted states, Ultrawide field-color photograph, Ultrawide field-Fluorescein angiogram, Optical coherence tomography, Optical coherence tomography- Angiography; Diagnostic Test · Other
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Huntington Beach, California • Augusta, Georgia • Boston, Massachusetts + 5 more

Conditions: Acute Myeloid Leukemia
Interventions: CPX-351, Venetoclax, Midostaurin, Enasidenib; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 10
States / cities: Duarte, California • Palo Alto, California • Augusta, Georgia + 7 more

Conditions: Solid Tumours
Interventions: selumetinib (oral); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Anxiety Disorders
Interventions: d-cycloserine and mifepristone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Congenital Lactic Acidosis
Interventions: Dichloroacetate (DCA), Genetic Marker on Chromosome 14q24.3; Drug · Genetic
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: HIV Infections
Interventions: HIV Test Offer, General Health Screen Offer; Behavioral
Lead sponsor: North Bronx Healthcare Network; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: CNS Malignancies, Medulloblastoma Recurrent, ATRT Recurrent, Pineoblastoma, Embryonal Neoplasm, Ependymoma Recurrent, High Grade Gliomas
Interventions: SGT-53, hypofractionated radiotherapy with immunotherapy, Nivolumab; Drug · Radiation
Lead sponsor: Children's National Research Institute; Other
Eligibility: 3 Years to 21 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Neoplasms
Interventions: Nilotinib and Paclitaxel; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Essential Hypertension
Interventions: perindopril erbumine; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Cancer
Interventions: Nivolumab, Dasatinib, Relatlimab, Ipilimumab, BMS-986205; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 35
States / cities: Duarte, California • Los Angeles, California • Newport Beach, California + 26 more

Conditions: Obesity
Interventions: 24-hour energy expenditure and substrate utilization; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 50 Years to 65 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Healthy Volunteers
Interventions: Mobocertinib; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Health Behavior, Diet, Healthy, Diet Habit
Interventions: Ready to Eat (RTE), Dried; Behavioral
Lead sponsor: Washington State University; Other
Eligibility: 19 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: ROHHAD, Rapid-Onset Obesity With Hypothalamic Dysfunction, Hypoventilation & Autonomic Dysregulation
Interventions: ROHHAD; Genetic
Lead sponsor: Ilya Khaytin; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2039
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced MTAP-null Solid Tumors
Interventions: Anvumetostat, Docetaxel, Comparator Anvumetostat Test Tablet; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 30
States / cities: Duarte, California • Glendale, California • Oxnard, California + 24 more

Conditions: Healthy
Interventions: OROS methylphenidate hydrochloride, methylphenidate hydrochloride; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Circulatory Failure, Cardiac Arrest
Interventions: rapid pulse confirmation device; Device
Lead sponsor: Michael Kyle Ritchie; Other
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation
Interventions: Metformin XR plus placebo, Metformin XR plus liraglutide; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Atherosclerosis, Diabetes, Coronary Artery Disease
Interventions: Nicotinamide riboside (NR), Placebo; Dietary Supplement · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 39 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: Intravenous hyperimmune immunoglobulin (Flu-IVIG), Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 11
States / cities: San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 8 more

Search by objective public record fields.

Traveling-wave Transcranial Electric Stimulation

COVID-19 iCura SARS-CoV-2 Ag OTC: Clinical Evaluation

Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

Prematurity and Respiratory Outcomes Program (PROP)

Longitudinal Natural History Study of Retinal Function in Eyes of Patients With Diabetes

A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia

To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers

Medication Enhanced Rapid Therapy

Pharmacotoxicology of Trichloroethylene Metabolites

The Feasibility of Using a General Health Screen to Increase HIV Testing in Community Pharmacies

A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions

An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

Impact of Black Pepper on Energy Expenditure and Substrate Utilization

A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants

Impact of Convenience on Whole Grain Consumption

International Rapid-onset Obesity With Hypothalamic Dysfunction, Hypoventilation & Autonomic Dysregulation (ROHHAD) Registry

A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults

Evaluation of Efficacy of the Prototype RPC (Rapid Pulse Confirmation) Device in Detecting Return of Pulsatile Flow in Patients Preparing to Separate From CPB (Cardiopulmonary Bypass)

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

Study to Evaluate the Effect of Nicotinamide Riboside on Immunity

Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)